Shares of global vaccine makers were mixed on Tuesday, as investors assessed U.S. Health Secretary Robert F. Kennedy Jr.'s ...

(Reuters) -Shares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach ...

The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

Vaccine stocks are rising after the FDA announced it will consider updating COVID-19 vaccines to target the rapidly spreading LP.8.1. The FDA will require new clinical trials for annual boosters ...

The controversy all has to do with a key government list of recommended vaccines and timing, called the CDC immunization schedule. Insurance companies and federal health programs often tie what ...

and its recommendations thus carry immense sway on pharma and biotech stocks, especially those with a sizable vaccine portfolio. Why It Matters: Kennedy has taken several steps against vaccination ...

Cheng Xin / Getty Images Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine. The shot, Nuvaxovid, is designed for older adults and those between the ...

The contract was expected to support the late-stage development and right to purchase pre-pandemic influenza vaccines, the Cambridge, Massachusetts-based biotech announced late Wednesday.

While the agency granted full approval to Nuvaxovid for use in older adults aged 65 and above, it restricted the vaccine’s use in individuals aged 12-64 with at least one underlying condition ...